Advertisement

MHC Class I Antigens In Malignant Cells

Immune Escape And Response To Immunotherapy

  • Natalia Aptsiauri
  • Angel Miguel Garcia-Lora
  • Teresa Cabrera

Part of the SpringerBriefs in Cancer Research book series (BRIEFSCANCER, volume 6)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
    Pages 1-11
  3. Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
    Pages 13-30
  4. Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera
    Pages 51-51

About this book

Introduction

Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​  

Keywords

Immunotherapy MHC class I cancer immune escape metastasis tumor rejection

Authors and affiliations

  • Natalia Aptsiauri
    • 1
  • Angel Miguel Garcia-Lora
    • 2
  • Teresa Cabrera
    • 3
  1. 1., Servicio de Análisis ClínicosHosp. Universitario Virgen de las NievesGranadaSpain
  2. 2.Hosp. Universitario Virgen de las NievesGranadaSpain
  3. 3., Servicio de Análisis ClínicosHosp. Universitario Virgen de las NievesGranadaSpain

Bibliographic information

Industry Sectors
Pharma
Biotechnology
Consumer Packaged Goods